Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disease characterized by
chronic hyperglycemia causing from insufficient insulin signaling because of insulin …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Background The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i)
on specific cardiovascular and renal outcomes and whether heterogeneity is based on key …

The pancreatic β-cell plays a key role in glucose homeostasis by secreting insulin, the only
hormone capable of lowering the blood glucose concentration. Impaired insulin secretion …

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …

Metabolic perturbations underlie a variety of cardiovascular disease states; yet, metabolic
interventions to prevent or treat these disorders are sparse. Ketones carry a negative clinical …

Despite current established therapy, heart failure (HF) remains a leading cause of
hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to …

Inhibition of the sodium–glucose cotransporter (SGLT) 2 in the proximal tubule of the kidney
has a broad range of effects on renal function and plasma volume homeostasis, as well as …

Non-alcoholic fatty liver disease (NAFLD) is an 'umbrella'term, comprising a spectrum
ranging from benign, liver steatosis to non-alcoholic steatohepatitis, liver fibrosis and …